Open Access

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17

  • Authors:
    • Ran Chen
    • Qi‑Tian Chen
    • You‑Hong Dong
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/ol.2019.10270
  • Pages: 5447-5452
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on the levels of serum IL‑17 were investigated. A retrospective analysis was performed on 129 patients who had metastatic gastric cancer after first‑line chemotherapy and were treated in Xiangyang No. 1 People's Hospital from February 2012 to February 2015. Of these patients, 78 received oral apatinib and were assigned to experimental group; and 51 received oral tegafur‑gimeracil‑oteracil and were assigned to control group. Clinical efficacy was compared between the two groups, and the levels of serum IL‑17 were measured for all the patients. The treatment response rate in the experimental group was 52.56% and in the control group 31.37%. Apparently, the treatment response rate in the experimental group was higher than that in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group (P<0.05). The serum level of IL‑17 after one course of medication was significantly lower than that before medication in both groups (P<0.05). In comparison between groups, the serum level of IL‑17 after one course of medication was clearly lower in the experimental group than that in the control group (P<0.05). Apatinib regimen was demonstrated to have less toxic side‑effects in the treatment of metastatic gastric cancer than tegafur‑gimeracil‑oteracil regimen, indicating that apatinib has favorable safety. In addition, apatinib can downregulate IL‑17 expression, which is helpful in attenuating tumor proliferation and improving the clinical efficacy. Therefore, apatinib has potential use in a wide range of clinical applications.

References

1 

Amieva M and Peek RM Jr: Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 150:64–78. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Guilford PJ: Markers for detection of gastric cancer. US Patent US 9,310,370 B2. Filed May 14, 2010; issued April 12. 2016.

3 

Liang H: Intraperitoneal chemotherapy for locally advanced gastric cancer to prevent and treat peritoneal carcinomatosis. Transl Gastroenterol Hepatol. 1:622016. View Article : Google Scholar : PubMed/NCBI

4 

Mikami J, Kimura Y, Makari Y, Sawada G, Nakahira S, Nakata K, Yamamoto T, Tsujie M and Ohsato H: A case of self-expandable metallic stent placement to treat colon obstruction due to metastatic gastric cancer. Gan To Kagaku Ryoho. 43:1899–1901. 2016.(In Japanese). PubMed/NCBI

5 

Ghosn M, Tabchi S, Kourie HR and Tehfe M: Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol. 22:3069–3077. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Hofmann F, Marconi LS, Stewart F, Lam TB, Bex A, Canfield SE and Ljungberg B: Targeted therapy for metastatic renal cell carcinoma (protocol). Cochrane Database Syst Rev. 9:CD0127962017.

7 

Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI

8 

Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Shen Q, Ma X, Hu W, Chen L, Huang J and Guo Y: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I–II natural killer/T-cell lymphoma nasal type: Dosimetric and clinical results. Radiat Oncol. 8:1522013. View Article : Google Scholar : PubMed/NCBI

10 

Wang N, Yang J, Lu J, Qiao Q, Bao G, Wu T and He X: IL-17 gene polymorphism is associated with susceptibility to gastric cancer. Tumour Biol. 35:10025–10030. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Maniati E, Soper R and Hagemann T: Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 29:5653–5662. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Nishiofuku H, Tanaka T, Sakaguchi H, Yamamoto K, Inoue M, Sueyoshi S, Shinnkai T, Hasegawa M and Kichikawa K: Hepatic arterial infusion chemotherapy combined with venous embolization in a patient with hepatic metastases with an arteriovenous shunt. Cardiovasc Intervent Radiol. 32:796–800. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Thomas RM and Sobin LH: Gastrointestinal cancer. Cancer. 75 (Suppl):154–170. 1995. View Article : Google Scholar : PubMed/NCBI

14 

Yoshida K, Yamaguchi K, Okumura N, Tanahashi T and Kodera Y: Is conversion therapy possible in stage IV gastric cancer: The proposal of new biological categories of classification. Gastric Cancer. 19:329–338. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Hsu PI, Chen CH, Hsieh CS, Chang WC, Lai KH, Lo GH, Hsu PN, Tsay FW, Chen YS, Hsiao M, et al: Alpha1-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer. Clin Cancer Res. 13:876–883. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, et al: Real-world treatment patterns among patients with advanced gastric cancer in South Korea. Cancer Res Treat. 49:578–587. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Zhang H: Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015. View Article : Google Scholar : PubMed/NCBI

19 

O'Brien RL, Roark CL and Born WK: IL-17-producing gammadelta T cells. Eur J Immunol. 39:662–666. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Martin-Orozco N and Dong C: The IL-17/IL-23 axis of inflammation in cancer: Friend or foe? Curr Opin Investig Drugs. 10:543–549. 2009.PubMed/NCBI

21 

Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Ma D, Zhu X, Zhao P, Zhao C, Li X, Zhu Y, Li L, Sun J, Peng J, Ji C and Hou M: Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol. 87:899–904. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Scott AJ, Messersmith WA and Jimeno A: Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 51:223–229. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Geng R and Li J: Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 16:117–122. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ and Finn RS: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, R., Chen, Q., & Dong, Y. (2019). Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17. Oncology Letters, 17, 5447-5452. https://doi.org/10.3892/ol.2019.10270
MLA
Chen, R., Chen, Q., Dong, Y."Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17". Oncology Letters 17.6 (2019): 5447-5452.
Chicago
Chen, R., Chen, Q., Dong, Y."Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17". Oncology Letters 17, no. 6 (2019): 5447-5452. https://doi.org/10.3892/ol.2019.10270